What Florida Pharmaceutical Products does

Florida Pharmaceutical Products, LLC (FPP) is a Boca Raton, Florida-based generic pharmaceutical company that develops, in-licenses, markets, and distributes FDA-approved generic prescription medications across 10+ therapeutic categories including oncology (Abiraterone, Exemestane, Mercaptopurine), antivirals (Tenofovir, Entecavir, Valganciclovir, Acyclovir), ALS (Riluzole), cardiovascular and ophthalmic agents, anticonvulsants (Lacosamide), and diabetes (Glimepiride). The company operates through three business models: organic ANDA development, in-licensing of ANDAs from international manufacturers, and asset acquisition — exemplified by the May 2020 purchase of Quinn Pharmaceuticals label assets. Its product surface is anchored by the FPP Label and the acquired Quinn Label product lines, with supply chain and manufacturing executed via 3PL partners and DSCSA-compliant packaging/labeling.

FPP was founded by Larry Runsdorf and is currently led by President Larry J. Lapila (a 35-year industry veteran). In May 2019 the company was acquired by Contract Pharmacal Corp. (CPC), a family-owned Hauppauge, NY-based pharmaceutical manufacturer with approximately 1,500 employees, and FPP is also identified as part of Indoco Remedies Ltd.'s group of companies. Capital and manufacturing capacity from CPC, combined with strategic alliances to Bluepharma (Portugal), Qilu Pharmaceutical (China), Inventia Healthcare (India), Standard Chem. & Pharm. (Taiwan), ONConcept (Europe), and Impopharma (Canada), provide FPP with cross-continental sourcing for both development-stage and FDA-approved generic candidates. The company filed its first internally developed ANDA in February 2020 (~$100M market opportunity per IQVIA) and achieved FDA approval of Abiraterone Acetate 500mg Tabs in September 2023 (generic of Zytiga, current generic market of $175M+).

FPP runs a sales-led, B2B distribution model targeting retail pharmacies, healthcare providers, and institutional buyers across the US market, with pricing executed through multi-year negotiated contracts and subject to federal/state government pricing programs. Revenue is generated through product sales plus licensing/royalty arrangements with manufacturing partners, with FPP providing order-to-cash services including chargeback processing, rebates, and gross-to-net accounting under tight DSCSA-compliance governance. The customer base is US-only and distributed across the healthcare system, with no public revenue disclosure available in the source material.

Name

Florida Pharmaceutical Products

Legal name

Florida Pharmaceutical Products, LLC

Website

https://flpharmaproducts.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Florida Pharmaceutical Products is a Boca Raton, FL-based generic pharmaceutical developer and distributor that in-licenses, develops, and markets FDA-approved generic prescription drugs across 10-plus therapeutic areas to US retail pharmacies, healthcare providers, and institutional buyers via a sales-led B2B distribution model.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Specialty Care Pharmaceuticals (HLAIAAAB), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Generic pharmaceuticals
• Prescription medications
• ANDA development
• Pharmaceutical distribution
• Generic drug licensing

Headquarters

HQ city

Boca Raton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Sales: FPP generates revenue through the development, licensing, sales, marketing, and distribution of generic pharmaceutical products. Revenue is derived from product sales to healthcare providers, pharmacies, and distribution partners across various therapeutic areas including oncology, antiandrogens, antivirals, and cardiovascular medications.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Florida Pharmaceutical Products (FPP) develops, licenses, markets, and distributes FDA-approved generic prescription medications across multiple therapeutic areas including oncology, antivirals, cardiovascular, ophthalmic, and neurological treatments. The company also provides integrated pharmaceutical services such as regulatory compliance, contract manufacturing, distribution, government pricing, and supply chain management to manufacturing partners and healthcare buyers in the US market.

Product overview

Florida Pharmaceutical Products, LLC (FPP) is a generic pharmaceutical company offering a broad portfolio of FDA-approved generic prescription medications across multiple therapeutic areas. The product portfolio includes branded sub-lines: FPP Label products covering antiandrogens (Abiraterone Acetate), xanthine oxidase inhibitors (Allopurinol), ophthalmic solutions (Brimonidine Tartrate, Dorzolamide Timolol), tricyclic psychotherapeutic agents (Doxepin), antivirals (Entecavir, Valganciclovir), oncology treatments (Exemestane), diabetes medications (Glimepiride), anticonvulsants (Lacosamide), opioid withdrawal treatment (Lofexidine), and migraine therapy (Sumatriptan); and Quinn Label acquired products including antivirals (Acyclovir), antispasmodics (Glycopyrrolate), antineoplastics (Mercaptopurine), ALS treatment (Riluzole), and antiretrovirals (Tenofovir). Beyond products, FPP provides integrated services including Research and Development, Business Development, Project Management, Sales and Marketing, Operations, Regulatory Compliance, Distribution, Financial Services, Government Pricing, and Contract Manufacturing. The company operates through various business models including Internal Development, Licensing, and Asset Acquisition, with a focus on bringing affordably priced generic medications from development to distribution.

Differentiator

Problem solved

Functional benefit

Products and services

• Abiraterone Acetate Tablets Generic antiandrogen tablets available in 250mg and 500mg strengths, indicated for treatment of metastatic castration-resistant and high-risk castration-sensitive prostate cancer in combination with prednisone.
• Allopurinol Tablets USP Generic xanthine oxidase inhibitor tablets in 100mg and 300mg strengths indicated for treatment of gout, kidney stones, and prevention of high uric acid levels in blood.
• Brimonidine Tartrate Ophthalmic Solution Generic alpha adrenergic receptor agonist ophthalmic solution in 0.2% strength, used for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
• Dorzolamide Timolol Ophthalmic Solution Generic topical carbonic anhydrase inhibitor/beta blocker combination ophthalmic solution (0.5%/2%) for treating increased eye pressure caused by glaucoma or ocular hypertension.
• Doxepin Hydrochloride Capsules Generic tricyclic psychotherapeutic capsules in 10mg, 25mg, 50mg, 75mg, and 100mg strengths for treatment of psychoneurotic patients with depression and/or anxiety.
• Entecavir Tablets Generic nucleoside analogue reverse transcriptase inhibitor tablets in 0.5mg and 1mg strengths for treatment of chronic hepatitis B virus infection.
• Exemestane Tablets Generic aromatase inhibitor tablets in 25mg strength for treatment of advanced breast cancer in postmenopausal women.
• Glimepiride Tablets USP Generic sulfonylurea tablets in 1mg, 2mg, and 4mg strengths used in management and treatment of type 2 diabetes mellitus.
• Lacosamide Tablets USP Generic anticonvulsant tablets in 50mg, 100mg, 150mg, and 200mg strengths used to control partial onset seizures in adults and children 1 month of age and older.
• Lofexidine Tablets Generic alpha-adrenergic agonist and antihypertensive tablets in 0.18mg strength indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.
• Sumatriptan Nasal Spray Generic serotonin receptor agonist nasal spray in 20mg strength for treatment of symptoms of migraine headache and cluster headache.
• Valganciclovir for Oral Solution Generic antiviral oral solution in 50mg/mL strength used to treat and prevent cytomegalovirus (CMV) infections of the eye and body.
• Quinn Label - Tenofovir Disoproxil Fumarate Tablets Generic antiretroviral tablets in 300mg strength indicated in combination with other antiretroviral agents for management of HIV-1 infection and treatment of chronic hepatitis B. Distributed under the Quinn Label.
• Quinn Label - Riluzole Tablets Generic benzothiazole tablets in 50mg strength indicated for treatment of patients with amyotrophic lateral sclerosis (ALS). Sold under Quinn Label in the US.
• Quinn Label - Acyclovir Capsule Generic antiviral/synthetic nucleoside analogue capsules in 200mg strength for treatment of infections caused by herpes viruses including genital herpes, cold sores, shingles, and chicken pox. Distributed under Quinn Label.
• Quinn Label - Glycopyrrolate Tablets Generic antispasmodic/anticholinergic tablets in 1mg and 2mg strengths used as adjunct in peptic ulcer disorders and to diminish secretions. Distributed under Quinn Label.
• Quinn Label - Mercaptopurine Tablets Generic antineoplastic/antimetabolite tablets in 50mg strength for maintenance therapy of acute lymphatic leukemia as part of a combination regimen; also for Crohn's disease and ulcerative colitis. Distributed under Quinn Label.

Quantifiable outcome

• Multiple ANDA approvals achieved, with Abiraterone 500mg Tablets representing a $175+ million market opportunity

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Seven partnerships are on record, tiered core.

• ONConcept (Bluepharma/Helm/Welding partnership)coreStrategic or Co-development Partner · 20 September 2023ONConcept developed Abiraterone 500mg Tablets ANDA generic for Zytiga. FPP manages US sales, marketing, and distribution. ONConcept is a strategic collaboration between Bluepharma (Portugal), Helm (Germany), and Welding (Germany) for oncology products. The product has peak sales exceeding $600 million with current generic sales of $175+ million.
• Standard Chem. & Pharm. Co., LtdcoreOEM/ Whitelabel/ Licensing Partner · 30 September 2020Licensing, supply, and distribution agreement for approved ANDA for Riluzole Tablets developed by Standard and approved by FDA. Standard is one of the leading pharmaceutical companies in Taiwan, founded in 1967 and publicly held since 1995. The product has sales of approximately $5 million according to IQVIA.
• Inventia Healthcare LimitedcoreOEM/ Whitelabel/ Licensing Partner · 1 April 2020Licensing, supply, and distribution agreement for ANDA developed by Inventia, recently approved by FDA. Inventia is headquartered in Mumbai, India with marketing partners across 28 countries for niche generic oral solid products. The product has sales of approximately $125 million according to IQVIA.
• Impopharma Canada Limited / Ayrton Saunders Ltd.coreOEM/ Whitelabel/ Licensing Partner · 16 October 2019Licensing agreement for niche generic ANDA developed by Impopharma Canada Limited (affiliate of Ayrton Saunders Ltd.). FPP will sell and distribute the product upon FDA approval. The product has sales of approximately $70 million according to IQVIA with limited generic competition.
• Qilu Pharmaceutical Co., Ltd.coreOEM/ Whitelabel/ Licensing Partner · 15 March 2019FPP manages sales, marketing, and distribution of Qilu's ANDA for Tenofovir 300mg Tablets in the US. Qilu is a leading vertically integrated pharmaceutical company in China. The product has current sales of $130 million according to IQVIA.
• Quinn Pharmaceuticals, LLCcoreStrategic or Co-development Partner · 4 February 2019Strategic alliance combining FPP's implementation expertise and industry relationships with Quinn's label and distribution capabilities. Deal creates end-to-end solution from procurement to order fulfillment, capitalizing on opportunities from Asia for US distribution. In May 2020, FPP acquired certain assets of Quinn Pharmaceuticals.
• Bluepharma Indústria Farmacêutica, S.A.coreStrategic or Co-development Partner · 9 January 2019Partnership for development and licensing of ANDA for a selective serotonin reuptake inhibitor (SSRI). Bluepharma develops the ANDA while FPP files with FDA and manages sales, marketing, and distribution. Bluepharma is a European pharmaceutical company based in Coimbra, Portugal.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Teva Pharmaceutical Industries: Global leader in generic pharmaceuticals with massive U.S. generics operation including oncology, cardiovascular, and CNS. Competes with FPP in multiple target markets as a broad incumbent, not a direct niche-specialist peer.
• Aurobindo Pharma USA: Large U.S. generic prescription operation of India-based Aurobindo Pharma with broad ANDA portfolio, in-licensing, and nationwide distribution. Broader incumbent with overlapping therapeutic coverage but greater scale and vertical integration.
• Dr. Reddy's Laboratories: India-based multinational with significant U.S. generics business spanning multiple therapeutic areas including oncology and ophthalmology. Comparable international sourcing model and broad generic portfolio, though at substantially larger scale.
• Sandoz (Novartis): Global generics and biosimilars division of Novartis with deep U.S. presence across all major therapeutic categories. Broad incumbent peer; overlaps with FPP in oncology and CNS generics but operates at vastly greater scale.

Direct peers

• Breckenridge Pharmaceutical: Privately-held U.S. generic Rx distributor and developer that in-licenses, develops, and distributes niche generic products across therapeutic categories. Closest direct comparable to FPP given overlapping model, shared alumni (multiple FPP executives previously at Breckenridge), and similar product breadth in niche generics.
• Zydus Pharmaceuticals USA: U.S. subsidiary of India-based Zydus Cadila developing and commercializing generic prescription products across multiple therapeutic areas. Comparable niche-and-broad-generic portfolio strategy and India-origin sourcing model similar to FPP's international partnership approach.
• Lannett Company: U.S.-based generic pharmaceutical manufacturer and distributor with broad portfolio across therapeutic areas including oncology, cardiovascular, and CNS. Comparable to FPP in product breadth and distribution model though larger in manufacturing scale.
• Camber Pharmaceuticals: U.S. generics subsidiary of Hetero Labs focusing on development, licensing, and distribution of niche generic prescription products across multiple therapeutic areas. Matches FPP's niche-generic, partnership-led, distribution-focused business model closely.
• ANI Pharmaceuticals: U.S. specialty generics company focused on niche, limited-competition generic prescription products across oncology, anti-infectives, and other therapeutic areas. Highly comparable business model: ANDA development, in-licensing, and specialty distribution.

Others

• Indoco Remedies Ltd. India-based publicly-listed pharmaceutical company identified as FPP's parent/group. Operates formulations manufacturing and international generics — directly comparable in therapeutic portfolio (including oncology, ophthalmology) and the originator of the pipeline that FPP distributes in the U.S.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/share.php?u=https://flpharmaproducts.com
• LinkedInlinkedin.com/company/florida-pharmaceutical-products-inc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Florida Pharmaceutical Products